Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/anthos-blood-thinner-cuts-the-risk-of-bleeding-amid-race-to-develop-safer-anticoagulants/
https://www.globenewswire.com/news-release/2023/06/26/2694288/0/en/Anthos-Therapeutics-Supported-Global-Survey-of-3000-Patients-Prescribed-Anticoagulants-Detailing-Impact-of-Patient-Relevant-Bleeding-PRB-Presented-at-ISTH-2023.html
https://www.globenewswire.com/news-release/2023/06/08/2684978/0/en/Regulatory-Authorities-in-China-and-Japan-Approve-Clinical-Trials-for-Anthos-Therapeutics-Dual-Acting-Factor-XI-XIa-Inhibitor-Abelacimab.html
https://www.globenewswire.com/news-release/2023/05/09/2664607/0/en/New-Assessment-Scale-to-Measure-Adherence-to-Oral-Anticoagulants-Based-on-Impact-of-Patient-Relevant-Bleeding-in-Atrial-Fibrillation-Presented-at-ISPOR-2023.html
https://www.globenewswire.com/news-release/2023/05/05/2662477/0/en/New-Assessment-Scale-to-Capture-Patient-Relevant-Bleeding-to-be-Presented-at-ISPOR-2023.html
https://www.globenewswire.com//news-release/2023/01/03/2582107/0/en/First-Patient-Enrolled-in-Phase-3-Trial-Evaluating-Abelacimab-in-High-Risk-Patients-with-Atrial-Fibrillation-Deemed-Unsuitable-for-Current-Anticoagulants.html
https://www.pharmaceutical-technology.com/news/fda-fast-track-anthos-abelacimab/
https://www.globenewswire.com/news-release/2022/08/25/2504559/0/en/Anthos-Therapeutics-Launches-Second-Phase-3-Clinical-Trial-of-Its-Dual-acting-Factor-XI-Inhibitor-Abelacimab.html